5d 1m 3m 1y 5y 10y
PVNAF vs. ETF Alternatives
Thursday, Sep 122013, 11:57 AM
Thursday, Sep 122013, 11:57 AM| 7 Comments
- Amarin (AMRN -7.8%) slides after a U.S. appeals court reverses an earlier ruling on generic Lovaza, finding in favor of Teva (TEVA +1%) and Par Pharmaceuticals and against GlaxoSmithKline (GSK -0.3%) and Lovaza partner Pronova (PVNAF.PK).
- The ruling looks to clear the way for generic Lovaza.
- Both AMRN's Vascepa and Lovaza are indicated for the treatment of high levels of triglycerides.
- Full court ruling